CIT - 医索

Randomized phase lllll trial of gemcitabine plusnab-paclitaxel versus. concurrentchemoradiotherapy with S-1 as neoadjuvanttreatment for borderline resectable pancreaticcancerGABARNANCE study

医客学院 - 会议报告集

A randomized phase ll study of gemcitapine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, andiposomal irinotecan in older patients with treatment-naivemetastatic pancreatic cance

医客学院 - 会议报告集

SACI-0 HR A randomized phase ll trial ofsacituzumab govitecan with or without pembrolizumabin patients with metastatic hormone receptor-positive!HER2-negative breast cancer

医客学院 - 会议报告集

ACE-Breast-02 a pivotal phase lllll trial of ARX788, anovel anti-HER2 ADC, vs lapatinib plus capecitabine forHER2 advanced breast cancer

医客学院 - 会议报告集

Sacituzumab Tirumotecan (sac-TMT; Also Known asSKB264MK-2870)in Combination With KL-A167 (Anti-PD-L1)as First-Line Treatment for Patients With Advanced NSCLCFrom the Phase ll OptiTRoP-Lung01 Study

医客学院 - 会议报告集

官宣！2024影响因子即将发布，将引入学科类别的统一排名，简化对期刊评估！

影响因子（Impact Factor，IF）是一个衡量学术期刊影响力的重要指标。由Web of Science平台发布的期刊引证报告（Journal Citation Reports, JCR）每年更新公布。2024年6月，又到了每年最新影响因子公布的时刻了。根据之前科睿唯安官.......

学术资讯 - 期刊资讯

复旦大学团队发文BMJ（IF=106）：1+1>2！PM 2.5和臭氧将加剧人群死亡

2023年10月4日，复旦大学阚海东教授团队，联合全球42个单位合作，在BMJ杂志上的发表了一篇题为“Interactive effects of ambient fine particulate matter and ozone on daily mortality in 372 cities: two stage time series analysis.....

学术资讯 - 临床研究

TROPHY-U-01 Cohort 3_Sacituzumab govitecan in combination with pembrolizumab in patients with mUC who progressed after platinum-based regimens

医客学院 - 会议报告集

posters-TROPiCS04_Study_of_sacituzumab_govitecan_SG_in_pat

医客学院 - 会议报告集

posters-TROPHYU01_cohort_4_Sacituzumab_govitecan_SG_in_com

医客学院 - 会议报告集